Wall Street Raises Bars on Hasbro and Pharma

Analysts lifted price targets across several sectors on Friday. The moves reflect broad confidence after a strong earnings season.

Hasbro saw the most notable consensus shift. The toymaker's average target rose to $109.29 from $109.07. That is a modest move, but 12 of 14 analysts now rate it a Hold. Short interest sits at just 4.6% of free float. Bears are not pressing hard here.

Regeneron Pharmaceuticals also drew target upgrades. The average price target climbed to $833.54 from $830.02. The biotech has a $74.8 billion market cap. Nine out of 17 analysts rate it a Buy. That bullish skew stands out in a sector facing pricing pressure.

Martin Marietta Materials was the notable downgrade target. Analysts trimmed the aggregates producer's average target to $671.61 from $676.48. One analyst added a Sell rating. Infrastructure spending optimism may be fading for this $31.5 billion construction materials giant.

Biogen targets also crept higher, to $234.35 from $233.87. The biotech space is drawing fresh attention. On the utilities side, Alliant Energy received a new recommendation, though consensus stayed neutral with nine Hold ratings in place.